XNCR - Xencor, Inc.
| Previous Close | 45.59 |
| Open | 45.42 |
| Bid | 44.58 x 800 |
| Ask | 44.60 x 1400 |
| Day's Range | 44.08 - 45.86 |
| 52 Week Range | 27.75 - 48.38 |
| Volume | 291,230 |
| Avg. Volume | 485,955 |
| Market Cap | 2.513B |
| Beta (3Y Monthly) | 1.05 |
| PE Ratio (TTM) | 64.62 |
| EPS (TTM) | 0.69 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.64 |
- Thomson Reuters StreetEvents•9 days ago
Edited Transcript of XNCR earnings conference call or presentation 9-May-19 8:30pm GMT
Q1 2019 Xencor Inc Earnings Call
- Simply Wall St.•12 days ago
What You Must Know About Xencor, Inc.'s (NASDAQ:XNCR) Financial Health
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Xencor, Inc...
- Markit•12 days ago
See what the IHS Markit Score report has to say about Xencor Inc.
Xencor Inc NASDAQ NMS:XNCRView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and increasing * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is moderately high for XNCR with between 10 and 15% of shares outstanding currently on loan. This represents an increase in short interest as investors who seek to profit from falling equity prices added to their short positions on July 5. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding XNCR is favorable, with net inflows of $4.63 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•19 days ago
Xencor (XNCR) Jumps: Stock Rises 7.4%
Xencor (XNCR) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- Business Wire•24 days ago
Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D.
Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that Paul Foster, M.D., senior vice president and chief medical officer at Xencor, plans to retire from Xencor effective October 31, 2019, following a transition period with a successor.
- Zacks•25 days ago
Company News For Jun 26, 2019
Companies in the news are: ABBV, AGN, LEN, XNCR, USNA and LION
- PR Newswire•27 days ago
MarketAxess Holdings Set to Join S&P 500; Axon Enterprise to Join S&P MidCap 400; Others to Join S&P SmallCap 600
NEW YORK , June 24, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent MarketAxess Holdings Inc. ...
- Insider Monkey•27 days ago
Here’s What Hedge Funds Think About Xencor Inc (XNCR)
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged during the first quarter. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 40% and 25% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted […]
- Simply Wall St.•last month
One Thing To Remember About The Xencor, Inc. (NASDAQ:XNCR) Share Price
Anyone researching Xencor, Inc. (NASDAQ:XNCR) might want to consider the historical volatility of the share price...
- Business Wire•2 months ago
Xencor Doses First Patient in Phase 1 Study of XmAb®22841 for the Treatment of Patients with Advanced Solid Tumors
Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the first patient has been dosed in a Phase 1 clinical study to evaluate the safety and tolerability of XmAb22841, both as a monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors. XmAb22841 is a bispecific antibody that simultaneously targets the immune checkpoint receptors CTLA-4 and LAG-3.
- Business Wire•2 months ago
Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development
Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced the appointment of Jeremy Grunstein, Ph.D., as vice president, business development. Dr. Grunstein brings more than 15 years of expertise in partnering, acquisitions and licensing in the biopharmaceutical industry and will lead strategic partnering to enhance the development of Xencor’s pipeline of drug candidates.
Motley Fool•2 months agoXencor Inc (XNCR) Q1 2019 Earnings Call Transcript
XNCR earnings call for the period ending March 31, 2019.
- Associated Press•2 months ago
Xencor: 1Q Earnings Snapshot
On a per-share basis, the Monrovia, California-based company said it had profit of $1.38. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- Business Wire•2 months ago
Xencor Reports First Quarter 2019 Financial Results
-- Management to Host Conference Call at 4:30 p.m. ET today --
- Business Wire•2 months ago
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and alle
- Business Wire•2 months ago
Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors
Xencor, Inc. (XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that the first patient has been dosed in XmAb23104-01 (DUET-3), a Phase 1 clinical study to evaluate the safety and tolerability of XmAb23104, a bispecific antibody that simultaneously targets the immune receptors PD-1 and ICOS, for the treatment of patients with advanced solid tumors.
- Business Wire•3 months ago
Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019
Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today announced that it will release first quarter 2019 financial results after the market closes on Thursday, May 9, 2019.
- Simply Wall St.•3 months ago
Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 24% Discount?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In this article we are going to estimate the intrinsic value of Xencor, Inc. (NASDAQ:XNCR) by ta...
